Pediatric hemophilia: A review

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 7, 2011, Pages 737-744

  Kulkarni, Roshni ^a   Soucie, J Michael ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

central venous access devices; Hemophilia; inhibitor; intracranial hemorrhage; newborns; pediatrics; prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CHILDHOOD DISEASE; CIRCUMCISION; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE SEVERITY; GENETICS; HEMARTHROSIS; HEMOPHILIA; ORAL BLEEDING; PRIORITY JOURNAL; RISK REDUCTION; X CHROMOSOME;

ADOLESCENT; CHILD; CIRCUMCISION, MALE; HEMARTHROSIS; HEMATOMA; HEMOPHILIA A; HUMANS; INFANT, NEWBORN; INTRACRANIAL HEMORRHAGES; MALE; MUSCULAR DISEASES;

EID: 84255177133     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1297164     Document Type: Conference Paper

References (51)

1. Soucie J M., Evatt B, Jackson D, The Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998 59 4 288-294 (Pubitemid 28543617)
2. Tagariello G, Iorio A, Santagostino E et al, Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009 114 4 779-784
3. Soucie J M., McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010 38 4, Suppl S475-S481
4. Kulkarni R, Soucie J M., Lusher J et al, Haemophilia Treatment Center Network Investigators. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009 15 6 1281-1290
5. World Federation of Hemophilia Report on the Annual Global Survey 2009. March 2011. Available at http://www.wfh.org/2/docs/Publications/Statistics/2009- Global-Survey-Report.pdf Accessed Oct 1, 2011
6. Evatt B L. The tragic history of AIDS in the hemophilia population, 1982-1984. J Thromb Haemost 2006 4 11 2295-2301 (Pubitemid 44575419)
7. Trimble S R., Parker C S., Grant A M., Soucie J M., Reyes N. Assessing emerging infectious threats to blood safety for the blood disorders community. Am J Prev Med 2010 38 4, Suppl S468-S474
8. Oldenburg J. Mutation profiling in haemophilia A. Thromb Haemost 2001 85 4 577-579 (Pubitemid 32293689)
9. Bolton-Maggs P H., Pasi K J. Haemophilias A and B. Lancet 2003 361 9371 1801-1809 (Pubitemid 36638432)
10. Monroe D M., Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006 26 1 41-48 (Pubitemid 43732226)
11. Baehner R L., Strauss H S. Hemophilia in the first year of life. N Engl J Med 1966 275 10 524-528
12. Chalmers E A. Haemophilia and the newborn. Blood Rev 2004 18 2 85-92 (Pubitemid 38380664)
13. Kenet G, Chan AKC, Soucie J M., Kulkarni R. Bleeding disorders in neonates. Haemophilia 2010 16 Suppl 5 168-175
14. Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001 112 2 264-274 (Pubitemid 32183467)
15. Rodriguez V, Titapiwatanakun R, Moir C, Schmidt K A., Pruthi R K. To circumcise or not to circumcise? Circumcision in patients with bleeding disorders. Haemophilia 2010 16 2 272-276
16. Pollmann H, Richter H, Ringkamp H, Jrgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999 158 Suppl 3 S166-S170 (Pubitemid 30014028)
17. Valentino L A. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010 8 9 1895-1902
18. Manco-Johnson M J., Abshire T C., Shapiro A D. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007 357 6 535-544 (Pubitemid 47236278)
19. Soucie J M., Cianfrini C, Janco R L. et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004 103 7 2467-2473 (Pubitemid 38392995)
20. Beyer R, Ingerslev J, Srensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia 2010 16 6 926-931
21. Nuss R, Soucie J M., Evatt B, Hemophilia Surveillance System Project Investigators. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol 2001 68 1 37-42 (Pubitemid 32738717)
22. Stieltjes N, Calvez T, Demiguel V et al, French ICH Study Group. Intracranial haemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 2005 11 5 452-458 (Pubitemid 41283112)
23. Ljung R C. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008 140 4 378-384
24. Kulkarni R, Lusher J M. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999 21 4 289-295 (Pubitemid 30316857)
25. Gupta S N., Kechli A M., Kanamalla U S. Intracranial hemorrhage in term newborns: management and outcomes. Pediatr Neurol 2009 40 1 1-12
26. Nakar C, Cooper D L., DiMichele D. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008). Haemophilia 2010 16 4 625-631
27. Ljung R. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is vaginal delivery. Haemophilia 2010 16 3 415-419
28. James A H., Hoots K. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery. Haemophilia 2010 16 3 420-424
29. Looney C B., Smith J K., Merck L H. et al. Intracranial hemorrhage in asymptomatic neonates: prevalence on MR images and relationship to obstetric and neonatal risk factors. Radiology 2007 242 2 535-541 (Pubitemid 46146206)
30. Smith A R., Leonard N, Kurth M H. Intracranial hemorrhage in newborns with hemophilia: the role of screening radiologic studies in the first 7 days of life. J Pediatr Hematol Oncol 2008 30 1 81-84
31. Wilson D A., Nelson M D. Jr, Fenstermacher M J. et al, The Hemophilia Growth and Development Study Group. Brain abnormalities in male children and adolescents with hemophilia: detection with MR imaging. Radiology 1992 185 2 553-558
32. Nelson M D. Jr, Maeder M A., Usner D et al. Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study. Haemophilia 1999 5 5 306-312 (Pubitemid 29495706)
33. Eyster M E., Gill F M., Blatt P M., Hilgartner M W., Ballard J O., Kinney T R. Central nervous system bleeding in hemophiliacs. Blood 1978 51 6 1179-1188 (Pubitemid 8344660)
34. Gouw S C., van der Bom J G., Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007 109 11 4648-4654 (Pubitemid 46827754)
35. Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 2010 16 Suppl 2 10-15
36. Kempton C L., White G C. II. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009 113 1 11-17
37. Verbruggen B, van Heerde W L., Laros-van Gorkom B A. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost 2009 35 8 752-759
38. Chitlur M, Warrier I, Rajpurkar M, Lusher J M. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009 15 5 1027-1031
39. DiMichele D. Inhibitors to factor VIII/IX: immune tolerance. In: Lee C Berntorp E Hoots K eds. Textbook of Hemophilia. UK Wiley-Blackwell 2010 66-74
40. Valentino L A., Kawji M, Grygotis M. Venous access in the management of hemophilia. Blood Rev 2011 25 1 11-15
41. Usner D W., Donfield S M., Sirois P A., Gomperts E D., Bale J F. Jr, Mitchell W G. Hemophilia morbidity, cognitive functioning, and academic achievement. J Pediatr 1998 133 6 782-787 (Pubitemid 28563949)
42. Shapiro A D., Donfield S M., Lynn H S. et al, Academic Achievement in Children with Hemophilia Study Group. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study. Pediatrics 2001 108 6 E105
43. Spencer M L., Wodrich D L., Schultz W, Wagner L, Recht M. Inattention, hyperactivity-impulsivity, academic skills and psychopathology in boys with and without haemophilia. Haemophilia 2009 15 3 701-706
44. Bladen M, Khair K, Liesner R, Main E. Long-term consequences of intracranial haemorrhage in children with haemophilia. Haemophilia 2009 15 1 184-192
45. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. MASAC document #195. 2010. The National. New York: National Hemophilia Foundation 116 West 32nd Street, New York, NY 10001 [Available at http://www.hemophilia.org]
46. Batorova A, Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006 13 5 308-315 (Pubitemid 44168450)
47. Morfini M. Secondary prophylaxis with factor IX concentrates: continuous infusion. Blood Transfus 2008 6 Suppl 2 s21-s25
48. Kulkarni R, Chitlur M, Lusher J. Treatment of congenital coagulopathies. In: Mintz P D. ed. Transfusion Therapy: Clinical Principles and Practice. 3rd ed. Bethesda, MD AABB Press 2011 167-208
49. Feldman B M., Pai M, Rivard G E. et al, Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006 4 6 1228-1236
50. Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009 23 6 267-274
51. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patientslong-term follow-up and continuing experience. Haemophilia. 2011 [Epub ahead of print]